54-1733F. TUBERCULIN PURIFIED PROTEIN DERIVATIVE PRODUCTS — SCREENING. Notwithstanding any other provision of law, a pharmacist acting in good faith and exercising reasonable care may prescribe and administer a tuberculin purified protein derivative product approved by the federal food and drug administration to a patient for the purpose of screening for tuberculosis infection, provided the following conditions are met:

(1) Prior to prescribing and administering a tuberculin purified protein derivative product, the pharmacist must successfully complete a course on proper test administration and interpretation of results from the United States centers for disease control and prevention (CDC) or a comparable course from a provider accredited by the accreditation council for pharmacy education;

(2) The pharmacist shall follow the recommendations for Mantoux tuberculin skin testing from the CDC regarding test administration and interpretation of results;

(3) Documentation of test results shall be maintained in the records of the pharmacy and a copy of the results shall be made available to the patient upon request; and

(4) If the patient is found to have a positive test reading:

(a) The pharmacist shall coordinate a timely referral to the patient’s primary care provider, if applicable, or to a local clinic to coordinate further diagnostics and follow-up care; and

(b) A report shall be submitted to the patient’s local health district or to the Idaho department of health and welfare in accordance with the rules governing Idaho reportable diseases.

History:

[(54-1733F) 54-1733E, added 2017, ch. 23, sec. 2, p. 43; am. and redesig. 2018, ch. 169, sec. 19, p. 369.]